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vival for blacks and whites with localized adenocarcinoma was 52.0% 
and 60.6%, while survival was 44.5% and 41.5% for blacks and whites 
with squamous cell carcinoma, respectively. With regard to age group 
comparisons, there was a signiﬁcant decrease in 5-year survival with 
advancing age among those with localized disease.
Conclusions: Differences in relative survival of lung cancer was 
strongly dependent upon histologic subtype. Indeed, ﬁve-year survival 
for adenocarcinoma of the lung is signiﬁcantly superior to that of other 
histologic subtypes. Improved survival in adenocarcinoma appears to 
be related to a more favorable stage distribution, which facilitates cura-
tive therapies
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Background: Sputum methylation analysis is feasible and by some 
studies suggested to show an increased risk for lung cancer. The aim of 
this study was to examine 6 methylation markers in sputum of patients 
with lung cancer and controls.
Methods: In the Canisius Wilhelmina Hospital Nijmegen sputum has 
been prospectively collected for several years of patients with lung 
cancer and controls. From this bank 102 cases with lung cancer and 
102 controls, most of them with COPD DNA was retrospectively 
extracted. Samples were subsequently randomized and blinded (TdB). 
Coded samples were exchanged between collaborators unaware of its 
origin. Quantitative MSP was performed for APC, Cytoglobin, MGMT, 
3-OST-2, p16, RASSF1A, and TCF21. Follow-up was retrieved inde-
pendently (MvdD). Pathology diagnosis was based on biopsy or only 
cytology. After submission of methylation data (to ZF with subsequent 
information of TdB) statistical analysis was performed (WY,ZF). 
Results: The pathology diagnosis was squamous cell carcinoma 
(n=23), adenocarcinoma (n=23), SCLC (n=16) or NSCLC not further 
speciﬁed. The 77 of the 102 controls had a Gold score for COPD >0. 
Sputum samples were collected within 6 months of lung cancer diagno-
sis. Follow-up of COPD cases was minimally 2 years.
Reproducibility of methylation analysis between two labs was poor for 
MGMT.
RASSF1A showed hypermethylation in 81 % of the SCLC and 69% of 
the NSCLC lung cancer cases with a speciﬁcity of 94 and 74%, respec-
tively. For two markers the sensitivity showed a decrease in sensitivity 
for SCLC and NSCLC to 50%, and 57%, respectively. The speciﬁcity 
increased for SCLC and NSCLC to 99 and 95%, respectively.
Conclusions: This blinded study shows that hypermethylation in spu-
tum is with two markers detects 50% of the lung cancer patients.
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Background: Concurrent chemoradiation is standard treatment for 
pts with inoperable stage III NSCLC. A previously reported single-
arm, phase II study by SWOG (Gandara et al JCO 2003) suggested D 
following EP/XRT further improved survival. We report results from 
a randomized, prospective phase III trial comparing EP/XRT with or 
without consolidation D.
Methods: Eligible pts had inoperable, stage IIIA/B NSCLC, PS 0-1 at 
study entry, FEV-1 > 1 L, and < 5% wt loss in the preceding 3 mos. Pts 
(n=243) received P 50 mg/m2 iv d 1,8,29,36 and E 50 mg/m2 iv d1-5, 
29-33 concurrently with chest XRT to 5940 cGy. Non-progressing pts 
(PS 0-2) were randomized to D 75 mg/m2 iv every 21 d for 3 cycles vs 
observation (O). The primary endpoint was to compare OS (Kaplan-
Meier analysis). A multivariate parametric accelerated failure time 
model was performed to identify factors that affected survival. Accrual 
of 259 pts to randomize 180 was planned to demonstrate a difference 
in MST of 25 vs 15 mos (5% 2-sided alpha, 80% power). Based upon 
evidence of futility (predeﬁned as p>0.7271), a DSMB recommended 
early termination after an analysis of the initial 203 pts. 
Results: Median f/u 25.6 mos. Pt characteristics (n=203): 34%/66% F:
M; median age 63; 39.4%/60.6% IIIA/B; staged with PET 66.5%; FEV-
1 > 2 46.7%; current smoker 41.9%. G3/4 toxicities during EP/XRT 
included 9.8% febrile neutropenia (FN), 17.2% esophagitis. 147 of 
203 pts (72.4%) were randomized to D (n=73) or O (n=74). 82.2% 
randomized to D received 3 cycles. G3/4 toxicities during D included: 
10.9% FN, 8.2% pneumonitis. 28.8% of pts were hospitalized during D 
(vs 8.1% in O arm) and 5.5% died due to D. Factors predictive for im-
proved survival included age < 70, FEV-1 > 2, and hemoglobin > 12 at 
baseline. PFS for D was 12.3 vs 12.9 mos for O (p=0.9412). The MST 
for all pts (n=203) was 21.15 mos; MST for D was 21.6 mos (95% C.I. 
17.7-35) vs 24.2 mos for O (95% C.I. 18.1-34.4) (p=0.9402). 
Conclusions: The MST with EP/XRT was higher than historical 
controls; however, consolidation D does not further improve survival, 
is associated with signiﬁcant toxicity including an increased rate of 
hospitalization and premature death.
